Cargando…

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study

OBJECTIVES: To conduct Japanese subgroup analyses of a randomized, global Phase II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma and to explore predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma. METHODS: The data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomita, Yoshihiko, Fukasawa, Satoshi, Oya, Mototsugu, Uemura, Hirotsugu, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Chen, Ying, Bair, Angel H., Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091032/ https://www.ncbi.nlm.nih.gov/pubmed/27572087 http://dx.doi.org/10.1093/jjco/hyw103

Ejemplares similares

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
por: Eto, Masatoshi, et al.
Publicado: (2014)

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study
por: Ozono, Seiichiro, et al.
Publicado: (2017)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
por: Tomita, Yoshihiko, et al.
Publicado: (2021)

Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
por: Tomita, Yoshihiko, et al.
Publicado: (2021)

Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
por: Tsukamoto, Taiji, et al.
Publicado: (2011)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2023)

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
por: Tamada, Satoshi, et al.
Publicado: (2021)

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study)
por: Tomita, Yoshihiko, et al.
Publicado: (2021)

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
por: Takayama, Koichiro, et al.
Publicado: (2022)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
por: Suzuki, Kazuhiro, et al.
Publicado: (2014)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
por: Numakura, Kazuyuki, et al.
Publicado: (2020)

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients
por: Akaza, Hideyuki, et al.
Publicado: (2015)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial
por: Oyama, Masafumi, et al.
Publicado: (2017)

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study
por: Sugiyama, Shigeru, et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
por: Eto, Masatoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g5u8c6ueobr03iqfpnt9l3m0iu